Results 101 to 110 of about 30,378 (204)

The effect of hearing Quran verses on reducing chemotherapy-induced nausea and vomiting in cancer patients referring to Imam Hossein Hospital

پژوهش در دین و سلامت, 2019
For downloading the full-text of this article please click here. Background and Objective: Nausea and vomiting are two common and disturbing adverse effect of chemotherapy.
Shaghayegh Kamian, Morteza Tabatabaeefar
doaj  

Triple HER2 Blockade With Trastuzumab, Pertuzumab, and Pyrotinib Versus Dual HER2 Blockade in the Neoadjuvant Treatment of HER2‐Positive Breast Cancer: A Randomized, Phase II Study

MedComm, Volume 7, Issue 2, February 2026.
Triple HER2 blockade with trastuzumab, pertuzumab, and pyrotinib (TPPy) did not improve total pathological complete response (tpCR) rates or breast pathological complete response (bpCR) rates compared with dual blockade with trastuzumab and pertuzumab (TP), but was associated with greater grade ≥ 3 toxicity, particularly diarrhea.
Jiahui Huang, Haoyu Wang, Yiwei Tong, Jin Hong, Yifei Zhu, Weili Ren, Jing Yu, Haoting Shi, Weiqi Gao, Siji Zhu, Jiayi Wu, Ou Huang, Jing Li, Jianrong He, Weiguo Chen, Yafen Li, Kunwei Shen, Xiaosong Chen   +17 more
wiley   +1 more source

Olanzapine plus triple antiemetic therapy for prevention of carboplatin-induced nausea: a pooled analysis of two clinical trials

BMC Cancer
Background Chemotherapy-induced nausea and vomiting is a common adverse event of cancer treatments. Despite prophylactic antiemetic treatment, nausea remains a particular problem. We aimed to identify risk factors and clarify the usefulness of olanzapine
Suguru Kojima, Naoki Inui, Takahito Suzuki, Kazuki Tanaka, Masato Karayama, Yusuke Inoue, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Koji Nishimoto, Shun Matsuura, Dai Hashimoto, Takashi Matsui, Kazuhiro Asada, Takafumi Suda   +17 more
doaj   +1 more source

A National Audit of Current UK Practice on the Use of Anti‐Emetics for Chemotherapy‐Induced Nausea and Vomiting in Children

Pediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT This UK national audit aimed to assess adherence to evidence‐based chemotherapy‐induced nausea and vomiting (CINV) guidelines for children with cancer, which emphasise treatment emetogenicity assessment, symptom monitoring and appropriate antiemetic use.
Eloise Neumann, Thomas J. Jackson, Jessica E. Morgan, Robert Phillips, Jessica Bate, the CCLG Supportive Care Group   +5 more
wiley   +1 more source

Third‐Generation EGFR‐TKIs Combined With Chemotherapy in Advanced Non‐Small Cell Lung Cancer: A Real‐World Study

Cancer Science, Volume 117, Issue 2, Page 476-490, February 2026.
This study was the largest sample size of first‐line third‐generation TKIs combined chemotherapy among advanced EGFRm NSCLC patients in the real world. It was never reported that aumolertinib and furmonertinib showed comparable PFS benefits to osimertinib in combination with chemotherapy. The overall safety profile remained acceptable. ABSTRACT FLAURA2
YuQin Jiang, Qi Liang, Yuting Zhu, Xiao Liang, Ruohan Huang, Wenxin Zhou, Chen Zhang, Jun Li, Jiali Xu, Renhua Guo   +9 more
wiley   +1 more source

Pharmacogenomics of Thiopurine Drugs: A Bench‐To‐Bedside Success Story in Thailand

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Thiopurine drugs are the cornerstone treatment for many diseases such as acute lymphoblastic leukemia (ALL), organ rejection, inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other autoimmune diseases.
Mohitosh Biswas, Shobana John, Murshadul Alam Murad, Chonlaphat Sukasem   +3 more
wiley   +1 more source

A pilot study of chemoimmunotherapy in the postconsolidation setting for high‐risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group

Cancer, Volume 132, Issue 2, 15 January 2026.
Abstract Background Survival for patients with high‐risk neuroblastoma remains poor despite current‐era multimodality treatment that includes postconsolidation GD2‐directed immunotherapy. Given the promising responses in patients who receive dinutuximab‐based chemoimmunotherapy in the relapsed setting, the Children’s Oncology Group ANBL19P1 study ...
Ami V. Desai, Arlene Naranjo, Brian LaBarre, Lulu Chen, Kelly C. Goldsmith, Meaghan P. Granger, Lisa States, Sean G. Green, Mariel Trunzo, Wendy Fitzgerald, Steven G. DuBois, Rochelle Bagatell, Julie R. Park, Araz Marachelian   +13 more
wiley   +1 more source

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab

Therapeutics and Clinical Risk Management, 2016
Mary Lou Affronti,1–3 Sarah Woodring,1,2 Katherine B Peters,1,4 James E Herndon II,5 Frances McSherry,5 Patrick N Healy,5 Annick Desjardins,1,4 James J Vredenburgh,6 Henry S Friedman1,2 1The Preston Robert Tisch Brain Tumor Center at Duke ...
Affronti ML, Woodring S, Peters KB, Herndon II JE, McSherry F, Healy PN, Desjardins A, Vredenburgh JJ, Friedman HS   +8 more
doaj  

Effectiveness of antiemetic regimens in controlling chemotherapy induced nausea and vomiting during hematopoietic stem cell transplantation. [PDF]

Sci Rep
Suárez-Casillas P, Ciudad-Gutiérrez P, Pérez-Moreno MA, Blázquez-Goñi C, Domínguez FMM, Pérez-Simón JA, Martín LA.   +6 more
europepmc   +1 more source

Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Platinum-Based Delayed-Phase Chemotherapy-Induced Nausea and Vomiting: A Meta-Analysis. [PDF]

Curr Oncol
Gong W, Qie H, Xu Y, Wang P, Gao J, Wang M.   +5 more
europepmc   +1 more source